Welcome to our dedicated page for Geovax Labs SEC filings (Ticker: GOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeoVax Labs, Inc. (GOVX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, giving investors a structured view of its capital markets activity, governance decisions, and development funding. As a smaller reporting company, GeoVax files registration statements, current reports, and proxy materials that outline its financing transactions, stockholder approvals, and contractual arrangements.
Through registration statements on Form S-1 and Form S-3, GeoVax registers offerings of common stock and warrants, as well as the resale of warrant shares issued in private placements. These filings describe offerings such as registered direct financings and concurrent private placements of common warrants, the number of shares and warrants involved, and intended uses of proceeds, including research and development, manufacturing, clinical studies, capital expenditures, and working capital.
Form 8-K current reports provide details on material events, including the pricing and closing of offerings, entry into placement agency and purchase agreements, government contract developments, and the release of quarterly financial results. 8-K filings also cover special stockholder meetings and the outcomes of votes on proposals such as warrant share issuance approvals and reverse stock split authorizations.
Proxy materials, such as the DEF 14A special meeting proxy statement, outline proposals submitted to stockholders, the rationale for actions like reverse stock splits or warrant exercise approvals, and the mechanics of voting. In addition, Form 25 filings document the removal from listing and/or registration of specific GeoVax securities, such as warrants, from Nasdaq Stock Market LLC.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex documents in plain language. Investors can quickly see the key terms of financing agreements, understand the implications of stockholder votes, and track how government contracts like the BARDA/Project NextGen award are reflected in the company’s disclosures. Real-time updates from EDGAR ensure that new 8-Ks, S-1s, proxy statements, and other filings are available promptly, while dedicated sections for warrant-related disclosures and capital structure changes help users follow the evolution of GOVX’s securities over time.
GeoVax Labs, Inc. filed a Form S-1 to register the resale of up to 11,904,768 shares of common stock issuable upon exercise of September 2025 warrants issued in a September 30, 2025 private placement. The company states it will not receive proceeds from Selling Stockholder sales; it would receive cash only if warrants are exercised.
If exercised for cash in full, gross proceeds would be approximately $7.5 million, intended for general corporate purposes and working capital. Shares outstanding were 29,705,360 as of October 17, 2025. The prospectus lists additional overhang figures, including 40,027,849 warrants outstanding with a weighted average exercise price of $0.70 per share, and option reserves under stock plans.
The filing notes the Nasdaq listing under “GOVX” and discloses a Nasdaq bid price deficiency with an initial compliance period through January 27, 2026.
GeoVax Labs (GOVX) called a Special Meeting on November 26, 2025 to seek stockholder approval for two actions. First, the company requests authorization to issue up to 11,904,768 shares of common stock upon exercise of its September 2025 Warrants at an exercise price of $0.63 per share, which expire five years after stockholder approval. These warrants include a 4.99% ownership blocker (increasable to 9.99% with notice) and price-adjustment features consistent with Nasdaq rules. If exercised in full, GeoVax notes potential gross proceeds of approximately $7,500,000.
Second, the Board seeks discretionary authority to implement a reverse stock split in a ratio between 1-for-10 and 1-for-25 to help regain compliance with Nasdaq’s $1.00 minimum bid requirement after a notice received on July 31, 2025, with the compliance period running to January 27, 2026. There were 29,705,360 shares outstanding as of September 30, 2025. The Board recommends voting FOR both proposals.
GeoVax Labs, Inc. filed an 8-K reporting a securities offering and related materials. The company engaged a placement agent and agreed to pay a cash fee equal to 7.0% of the gross proceeds plus reimbursement of certain expenses and legal fees. The Shares were offered under a Prospectus Supplement to an S-3 registration statement declared effective March 13, 2024 (File No. 333-277585). The company will issue accompanying Common Warrants and intends to issue the Warrant Shares pursuant to exemptions under Section 4(a)(2) and/or Rule 506(b) of Regulation D. Legal opinion and form agreements and exhibits are filed or incorporated by reference, and a press release dated September 30, 2025 announcing pricing is attached as an exhibit.
GeoVax Labs, Inc. is offering 3,968,256 shares of common stock at $0.63 per share, raising gross proceeds of about $2.5 million and estimated net proceeds of roughly $2.3 million. The stock is sold through Roth Capital Partners as placement agent on a best-efforts basis, with no minimum offering amount or escrow.
Each share is coupled with three common warrants sold in a concurrent private placement, allowing the purchase of up to 11,904,768 additional shares at $0.63 per share, immediately exercisable for five years, subject to a 4.99% beneficial ownership cap. The company plans to use the cash primarily to advance its vaccine and immunotherapy pipeline, including research, manufacturing, clinical studies and working capital.
As of September 29, 2025, GeoVax had 25,737,104 shares outstanding, which would rise to 29,705,360 shares after this offering. The company reports a history of operating losses, a going concern opinion, significant additional capital needs, and a recent Nasdaq notice for failing to meet the $1.00 minimum bid requirement, highlighting substantial ongoing financial and listing risks for investors.
GeoVax Labs, Inc. (GOVX) submitted a Form 25 notification regarding removal of a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office in Smyrna, Georgia and includes Nasdaq's certification that it has complied with the applicable rule provisions for striking the class from the Exchange. The form references rule provisions under 17 CFR 240.12d2-2 and notes Form 25 and an attached notice satisfy related procedural requirements.
GeoVax Labs, Inc. may currently offer and sell shares of its common stock with an aggregate offering price of up to approximately $5,925,259 under its existing at‑the‑market stock offering program with A.G.P./Alliance Global Partners. This prospectus supplement updates earlier prospectuses after the company became subject to Form S‑3 General Instruction I.B.6, which limits primary offerings to no more than one‑third of the public float in any twelve‑month period while the float remains below $75 million.
Under the original prospectus, GeoVax registered up to $30,000,000 of common stock for sale through the ATM and has already sold 3,964,770 shares for gross proceeds of $8,950,918. The aggregate market value of common stock held by non‑affiliates is about $21,548,168, based on 25,320,996 non‑affiliate shares at $0.851 per share as of July 23, 2025, and the company has sold approximately $1,257,464 of securities under I.B.6 in the past twelve months.